Benorilate

Summary

Benorilate (CHEMBL162036) is an approved small molecule (ATC N02BA10); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02BA10
• Indications: 2 conditions
• Chemistry: 313.3 Da · C17H15NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL162036
Name	Benorilate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	21102
ATC	N02BA10
Molecular formula	C17H15NO5
Molecular weight	313.3
InChIKey	FEJKLNWAOXSSNR-UHFFFAOYSA-N

SMILES: CC(=O)NC1=CC=C(C=C1)OC(=O)C2=CC=CC=C2OC(=O)C

IUPAC name: (4-acetamidophenyl) 2-acetyloxybenzoate

Also known as: Benorilate, Benorilato, Benorylate, Triadol, WIN 11450, WIN-11450, SID50112722, BENORILATE, SID144206025, SID170466237

Patent coverage: 2,631 distinct patent families (11,058 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,039 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Nuclear receptor ROR-gamma.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).